Abvc Biopharma (ABVC) Non-Current Assets (2010 - 2026)
Abvc Biopharma's (ABVC) quarterly Non-Current Assets came in at $19.1 million in Q1 2026, up 207.78% YoY from $6.2 million in Q1 2025, and up 8184.07% on a QoQ basis from $230366.0 in Q4 2025.
Abvc Biopharma (ABVC) Non-Current Assets (2010 - 2026) Analysis & Trends
Abvc Biopharma (ABVC) has 15 years of Non-Current Assets data on file, last reported at $19.1 million in Q1 2026.
- Quarterly Non-Current Assets rose 207.78% year-over-year to $19.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $48.1 million (up 202.7% YoY) and the FY2025 annual result came in at $230366.0, down 78.74% from the prior year.
- Non-Current Assets grew to $19.1 million in Q1 2026, from $230366.0 in the prior quarter.
- In the past five years, Non-Current Assets ranged from a high of $19.1 million in Q1 2026 to a low of $230366.0 in Q4 2025.
- A 5-year average of $4.0 million and a median of $801410.0 in 2023 frame the typical range for Non-Current Assets.
- Annual changes were most pronounced in 2022 — Non-Current Assets slumped 87.33% — and 2024, when it jumped 1203.12%.
- Tracing ABVC's Non-Current Assets over 5 years: stood at $739472.0 in 2022, then fell by 7.2% to $686206.0 in 2023, then soared by 57.89% to $1.1 million in 2024, then tumbled by 78.74% to $230366.0 in 2025, then soared by 8184.07% to $19.1 million in 2026.
- The last three Non-Current Assets figures came in at $19.1 million (Q1 2026), $230366.0 (Q4 2025), and $17.9 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.88 Bn | 132.03 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.62 Bn | 78.62 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.28 Bn | 60.10 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 61.39 Bn | 56.25 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.11 Bn | 37.01 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.37 Bn | 28.06 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 28.76 Bn | 10.37 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.41 Bn | - | 18.06 Bn |
| 10 | Abvc Biopharma | 23.97 Mn | 23.97 Mn | - | 18.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 18.99 Mn |
| Mar 31, 2026 | 19.08 Mn |
| Dec 31, 2025 | 230,366.00 |
| Sep 30, 2025 | 17.90 Mn |
| Jun 30, 2025 | 4.90 Mn |
| Mar 31, 2025 | 6.20 Mn |
| Dec 31, 2024 | 1.08 Mn |
| Sep 30, 2024 | 5.61 Mn |
| Jun 30, 2024 | 3.26 Mn |
| Mar 31, 2024 | 651,560.00 |
| Dec 31, 2023 | 686,206.00 |
| Sep 30, 2023 | 651,221.00 |
| Jun 30, 2023 | 250,077.00 |
| Mar 31, 2023 | 801,410.00 |
| Dec 31, 2022 | 739,472.00 |
| Sep 30, 2022 | 740,874.00 |
| Jun 30, 2022 | 330,231.00 |
| Mar 31, 2022 | 4.08 Mn |
| Dec 31, 2021 | 374,423.00 |
| Sep 30, 2021 | 2.53 Mn |